on the treatment of degenerative and functional mitral valve disease causing mitral regurgitation.
is the percutaneous treatment of mitral regurgitation with novel medical devices that respect the proven principles of mitral valve surgery, both mitral valve repair and replacement.
Who We are
Dr. Peter Skarsgard, MD
President, Chief Scientific Officer
Dr. Skarsgard is a Cardiovascular Surgeon and Clinical Associate Professor of Surgery at the University of British Columbia, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital. His area of expertise is mitral valve repair and complex valvular surgery. Based upon a simple clinical observation, Dr. Skarsgard developed and patented concepts for devices aimed toward percutaneous treatment of mitral regurgitation, utilizing proven surgical principles. These ideas form the basis for Calla and Orion.
Vincent Ledoux, MSc
Chief Operating Officer
Mr. Ledoux is a Business and Strategy Specialist with a background in Corporations and Investment Banking worldwide. Since 2009, he has been deeply involved in startups – launching, advising and mentoring engineering and technology ventures. Vincent holds a Bachelor of Science in Economics and a Master of Science in Business Management from EMLyon Business School in France. While bringing valuable corporate and business inputs, Vincent will manage the day-to-day activities and coordinate the R&D.
The Clinical Advisory
Dr. Jacqueline Saw, MD
Interventional Cardiology Advisor
Dr. Saw is a Clinical Professor of Medicine at the University of British Columbia, and a Structural Interventional Cardiologist at the Vancouver General Hospital. She is a recognized expert and key opinion leader in percutaneous device delivery, left atrial appendage occlusion, and spontaneous coronary artery dissection. Her contributions in CT imaging, pre-procedural planning, device selection, and device delivery have enabled acceleration of evolving structural interventions. She has considerable clinical trial experience, and has been a driving force for understanding women’s health in cardiovascular disease. Dr. Saw will lead the pre-procedure planning and device delivery effort, and bring important clinical trial design input to Vesalius Cardiovascular.
Dr. Christopher Durkin, MD
Dr. Durkin is a Clinical Assistant Professor of Anaesthesiology at the University of British Columbia, and a member of the Section of Cardiovascular Anaesthesiology at Vancouver General Hospital. In addition to expertise in cardiovascular physiology and pharmacology, he holds National Board of Echocardiography Certification in Advanced Perioperative Transesophageal Echocardiography, and is an expert in 3D echo for intracardiac structural disease and procedures. Dr. Durkin brings critical inputs in 3D echo imaging, both procedurally and in planning, to Vesalius Cardiovascular.